Targeted therapies, in particular targeted radionuclidetherapy(TRT), offer a unique opportunity to overcome many shortcomings ofexisting therapeutic approaches. Theseapproaches utilize antibodies or small molecules, which recognizeand bind to cell surface receptors overexpressed on the disease targetto selectively deliver therapeutic payloads to the disease site. One of the key targets with success in this spaceis prostate-specific membrane antigen (PSMA), which is overexpressedin the majority of prostate cancers, making this an appealing diseasetarget for both imaging and therapy. This evidence concerns the gene FOLH1 and prostate carcinoma.